The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib

BACKGROUND: Chronic myeloid leukaemia is in principle a treatable malignancy but drug resistance is lowering survival. Recent drug discoveries have opened up new options for drug combinations, which is a concept used in other areas for preventing drug resistance. Two of these are (I) Axitinib, which...

Descripción completa

Detalles Bibliográficos
Autores principales: G. Lindström, H. Jonathan, Friedman, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204252/
https://www.ncbi.nlm.nih.gov/pubmed/32380976
http://dx.doi.org/10.1186/s12885-020-06782-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204252/
https://www.ncbi.nlm.nih.gov/pubmed/32380976
http://dx.doi.org/10.1186/s12885-020-06782-9

Ejemplares similares